Drug class
Glucagon-Like Peptide-1 Receptor Agonists clinical trials
A class of medicines: the studies that test any of its 11 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the glucagon-like peptide-1 receptor agonists studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
Studies by the year they started
1,395 studies that test it; most in 2026 (153); 10 more planned to start later
| Year | Studies |
|---|---|
| 1999 | 3 |
| 2000 | 1 |
| 2001 | 6 |
| 2002 | 9 |
| 2003 | 7 |
| 2004 | 6 |
| 2005 | 12 |
| 2006 | 29 |
| 2007 | 24 |
| 2008 | 35 |
| 2009 | 40 |
| 2010 | 39 |
| 2011 | 44 |
| 2012 | 58 |
| 2013 | 58 |
| 2014 | 67 |
| 2015 | 50 |
| 2016 | 68 |
| 2017 | 58 |
| 2018 | 33 |
| 2019 | 69 |
| 2020 | 45 |
| 2021 | 72 |
| 2022 | 71 |
| 2023 | 94 |
| 2024 | 122 |
| 2025 | 122 |
| 2026 | 153 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Obesity
- 224
Who runs them
Industry 690 · Other 717
Novo Nordisk A/S (285) · Eli Lilly and Company (172) · AstraZeneca (82) · Boehringer Ingelheim (35) · GlaxoSmithKline (34) · University Medical Centre Ljubljana (15) · BrightGene Bio-Medical Technology Co., Ltd. (13) · Mayo Clinic (12)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 1,407
- Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.RecruitingPhase 2/3McGill University Health Centre/Research Institute of the McGill University Health CentreNCT07891156Written as Semaglutide
- A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusRecruitingPhase 3AstraZenecaNCT07662213Written as Elecoglipron
- GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way ForwardNot yet recruitingPhase 4University of MinnesotaNCT06977438Written as Semaglutide
- Tirzepatide Titration to Reduce Side Effects in Individuals With ObesityRecruitingNot applicableDasman Diabetes InstituteNCT07574723Written as Tirzepatide (Per-label titration)
- PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility StudyRecruitingPhase 2M.D. Anderson Cancer CenterNCT07874828Written as Tirzepatide
- A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 DiabetesNot yet recruitingPhase 3Eli Lilly and CompanyNCT07881458Written as eloralintide and tirzepatide
- Semaglutide for the Treatment of Cannabis Use DisorderNot yet recruitingPhase 2Massachusetts General HospitalNCT07879612Written as semaglutide
- A Study of EloraTZP in Adult Participants With Obesity Without Type 2 DiabetesNot yet recruitingPhase 3Eli Lilly and CompanyNCT07881432Written as eloralintide and tirzepatide
- The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 DiabetesRecruitingPhase 2Mayo ClinicNCT06976619Written as Liraglutide Pen Injector
- A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesRecruitingPhase 3Eli Lilly and CompanyNCT07668336Written as Orforglipron
- ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver DiseaseNot yet recruitingPhase 3Boehringer IngelheimNCT07850063Written as Survodutide
- A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide MedicationRecruitingPhase 1Novo Nordisk A/SNCT07855133Written as Semaglutide
- A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide MedicationRecruitingPhase 1Novo Nordisk A/SNCT07868354Written as Tirzepatide
- Short Term Effects of Semaglutide on Body Composition and PerformanceNot yet recruitingNot applicableMorten Hostrup, PhDNCT07874971Written as Semaglutide (SEMA)
- Long-Term Effects of Semaglutide on Body Composition and Performance in RunningNot yet recruitingNot applicableMorten Hostrup, PhDNCT07874932Written as Semaglutide (SEMA)
- Therapeutic Strategies for Microvascular Dysfunction in Type 1 DiabetesRecruitingPhase 2AdventHealth Translational Research InstituteNCT05478707Written as Dulaglutide
- A Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without DiabetesRecruitingPhase 2BrightGene Bio-Medical Technology Co., Ltd.NCT07658560Written as BGM0504 tablets
- SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose WeightNot yet recruitingPhase 3Boehringer IngelheimNCT07850050Written as Survodutide
- FutureShape FamilyNot yet recruitingPhase 4Signe TorekovNCT07872904Written as Semaglutide (administered by PDS290 pen-injector)
- LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisRecruitingPhase 3Boehringer IngelheimNCT06632444Written as Survodutide
See all 1,407 studies that test one of the glucagon-like peptide-1 receptor agonists →
Codes
What other systems call Glucagon-Like Peptide-1 Receptor Agonists · ClinicalTrials.gg INT006883
- MeSH (NLM) D000097789Glucagon-Like Peptide-1 Receptor AgonistsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000097789 | Glucagon-Like Peptide-1 Receptor Agonists | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.